Physician profile
Philip Rabito
NPI 1487648176
$712,476.32
in general payments reported to CMS, 2019-2025
60 companies · $71K in 2025
The $71K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $71K · 2020: $71K · 2021: $83K · 2022: $172K · 2023: $139K · 2024: $105K · 2025: $71K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $140K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $126K · Food and Beverage: $27K · Consulting Fee: $13K · Travel and Lodging: $9,257 · Education: $93.18.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $140,077.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $125,815.57 |
| Food and Beverage | $27,328.82 |
| Consulting Fee | $13,305.00 |
| Travel and Lodging | $9,257.37 |
| Education | $93.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $134,918.69 | 2020-2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $118,746.18 | 2022-2025 | Recorlev, Gvoke Hypopen |
| Janssen Pharmaceuticals, INC | $90,339.33 | 2019-2023 | Xarelto |
| Intuity Medical INC | $70,352.72 | 2022-2023 | Pogo Automatic Blood Glucose Monitoring System |
| Amryt Pharma Holdings LTD | $64,511.67 | 2021-2023 | Mycapssa |
| Intra-Sana Laboratories | $43,442.96 | 2023-2025 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Novo Nordisk INC | $40,009.12 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Merck Sharp & Dohme LLC | $37,075.13 | 2019-2024 | Verquvo |
| Zealand Pharma US, INC. | $31,852.75 | 2020-2021 | |
| Cequr Corporation | $21,520.49 | 2023-2025 | Cequr Simplicity |
| Abbvie INC. | $13,271.98 | 2019-2025 | |
| Mannkind Corporation | $11,838.40 | 2019-2025 | Afrezza |
| Amgen INC. | $7,615.87 | 2019-2025 | Tepezza, Repatha, Repatha |
| Recordati_rare_diseases_inc. | $3,705.17 | 2022-2025 | Isturisa, Signifor Lar |
| Chiasma, INC. | $3,117.50 | 2021 |
Show all 60 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,980.43 | 2019-2025 | Jardiance |
| Vistapharm, INC. | $2,279.84 | 2021 | |
| Lilly USA, LLC | $1,694.05 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Ibsa Pharma INC. | $1,366.96 | 2019-2024 | Tirosint, Tirosint, Licart |
| Pfizer INC. | $1,255.47 | 2020-2025 | |
| Sanofi-Aventis U.S. LLC | $1,195.52 | 2019-2025 | |
| Nevro Corp. | $1,050.70 | 2020-2024 | Senza |
| Bayer Healthcare Pharmaceuticals INC. | $802.37 | 2022-2025 | |
| Abbott Laboratories | $752.25 | 2020-2023 | Freestyle Libre 3, Proclaim, Freestyle Libre 2 |
| Amneal Pharmaceuticals LLC | $620.34 | 2021-2025 | Unithroid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $555.42 | 2019-2023 | Cycloset |
| Esperion Therapeutics, INC. | $515.63 | 2020-2025 | Nexletol |
| Astrazeneca Pharmaceuticals LP | $515.58 | 2019-2025 | Breztri, Farxiga, Lokelma |
| Ascendis Pharma Endocrinology INC | $468.25 | 2023-2025 | Yorvipath |
| Madrigal Pharmaceuticals | $463.24 | 2025 | Rezdiffra |
| Biohaven Pharmaceutical Holding Company LTD. | $428.82 | 2022 | |
| Novartis Pharmaceuticals Corporation | $420.43 | 2023-2025 | |
| Antares Pharma, INC. | $354.57 | 2022-2025 | Xyosted, Nocdurna, Tlando |
| Eusa Pharma (US) LLC | $330.74 | 2022 | |
| Currax Pharmaceuticals LLC | $215.50 | 2021-2025 | Contrave, Nexletol, Nexlizet |
| Kyowa Kirin, INC. | $198.76 | 2023-2025 | Crysvita |
| Heartflow, INC. | $192.03 | 2024-2025 | |
| Medtronic, INC. | $186.59 | 2021-2024 | Minimed 780g |
| Horizon Therapeutics Plc | $158.46 | 2020-2023 | Tepezza |
| Biohaven Pharmaceuticals, INC. | $150.00 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $139.87 | 2019-2023 | Somatuline Depot |
| Astellas Pharma US INC | $138.41 | 2023-2024 | Veozah |
| Gilead Sciences, INC. | $124.89 | 2019 | |
| Aytu Biopharma, INC. | $84.52 | 2019-2020 | |
| Acerus Pharmaceuticals Corporation | $52.50 | 2020-2022 | |
| Alexion Pharmaceuticals, INC. | $52.04 | 2025 | Strensiq |
| Theratechnologies INC. | $44.96 | 2025 | Egrifta, Trogarzo |
| Verity Pharmaceuticals INC. | $43.98 | 2024 | Tlando |
| Janssen Scientific Affairs, LLC | $41.81 | 2019 | |
| Tolmar, INC. | $40.34 | 2024-2025 | Jatenzo |
| Azurity Pharmaceuticals, INC. | $39.03 | 2025 | Azmiro |
| Boston Scientific Corporation | $35.35 | 2025 | Ams 700 |
| Rhythm Pharmaceuticals, INC. | $29.94 | 2025 | Imcivree |
| Renalytix Ai, INC. | $22.54 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Ascensia Diabetes Care US INC. | $22.26 | 2025 | |
| Grt US Holding, INC. | $21.59 | 2022 | |
| Halozyme INC | $19.70 | 2023 | |
| Evoke Pharma, INC. | $19.47 | 2025 | |
| Althera Pharmaceuticals LLC | $18.58 | 2021 | |
| Vivus LLC | $14.63 | 2023 | Qsymia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Rabito listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.